Condition
Myasthenia Gravis Associated With Thymoma
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07571525Not Yet Recruiting
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
NCT07231523Phase 3Not Yet Recruiting
EFG vs IVIG in TAMG
NCT06617741Recruiting
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT05262582Not ApplicableUnknown
Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy
NCT03468452CompletedPrimary
Early Versus Late Extubation in Myasthenia Gravis Patients
Showing all 5 trials